Search research articles
Contact Us
Filters
Showing results (221-230 of 237) with videos related to
Page
of 24
Sort By:
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
October 17, 2025
Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma
Maryam Safari, Luigi Scotto, Agnes Basseville, et al.
Cancer Research
|
April 19, 2003
HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo
Frank Loganzo, Carolyn M Discafani, Tami Annable, et al.
The Journal of Clinical Investigation
|
November 22, 2016
Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome
Ping-Yuan Wang, Jie Li, Farzana L Walcott, et al.
The American Journal of Cardiology
|
April 22, 2015
Succinate dehydrogenase gene mutations in cardiac paragangliomas
Victoria L Martucci, Abbas Emaminia, Jaydira del Rivero, et al.
Oncotarget
|
November 2, 2017
Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using <sup>64</sup>Cu-plerixafor PET
Ido D Weiss, Lyn M Huff, Moses O Evbuomwan, et al.
Oncotarget
|
October 24, 2018
Correction: Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using <sup>64</sup>Cu-plerixafor PET
Ido D Weiss, Lyn M Huff, Moses O Evbuomwan, et al.
Blood
|
March 1, 2011
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Richard L Piekarz, Robin Frye, H Miles Prince, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2009
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma
Richard L Piekarz, Robin Frye, Maria Turner, et al.
British Journal of Haematology
|
April 21, 2015
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data
Susan E Bates, Robin Eisch, Alexander Ling, et al.
Endocrine-Related Cancer
|
September 29, 2016
Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome
Roland Därr, Joan Nambuba, Jaydira Del Rivero, et al.
Page
of 24
Search research articles
Search
Showing results (221-230 of 237) with videos related to
Sort By:
Page
of 24
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
October 17, 2025
Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma
Maryam Safari, Luigi Scotto, Agnes Basseville, et al.
Cancer Research
|
April 19, 2003
HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo
Frank Loganzo, Carolyn M Discafani, Tami Annable, et al.
The Journal of Clinical Investigation
|
November 22, 2016
Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome
Ping-Yuan Wang, Jie Li, Farzana L Walcott, et al.
The American Journal of Cardiology
|
April 22, 2015
Succinate dehydrogenase gene mutations in cardiac paragangliomas
Victoria L Martucci, Abbas Emaminia, Jaydira del Rivero, et al.
Oncotarget
|
November 2, 2017
Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using <sup>64</sup>Cu-plerixafor PET
Ido D Weiss, Lyn M Huff, Moses O Evbuomwan, et al.
Oncotarget
|
October 24, 2018
Correction: Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using <sup>64</sup>Cu-plerixafor PET
Ido D Weiss, Lyn M Huff, Moses O Evbuomwan, et al.
Blood
|
March 1, 2011
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Richard L Piekarz, Robin Frye, H Miles Prince, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2009
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma
Richard L Piekarz, Robin Frye, Maria Turner, et al.
British Journal of Haematology
|
April 21, 2015
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data
Susan E Bates, Robin Eisch, Alexander Ling, et al.
Endocrine-Related Cancer
|
September 29, 2016
Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome
Roland Därr, Joan Nambuba, Jaydira Del Rivero, et al.
Page
of 24